MYCN and cancer: A drug toxicity test in healthy PBMCs revealed lower sensitivity to ceftriaxone compared with MYCN‐amplified cancer cells but similar sensitivity to MYCN‐nonamplified cancer cells, as indicated by the IC50 values (Fig. 1H,I).